Market Challenges And Opportunities

Rising prevalence of hemophilia drives the hemostasis diagnostics market globally

The critical nature of the procedure in the field of medicine and healthcare has gained a prominent position in the hemostasis diagnostics market. According to the National Hemophilia Foundation in 2012, the global incidence of hemophilia is estimated to be 400,000 people. The rise in the prevalence of genetically inherited disorders such as hemophilia, an increase in the number of surgeries and trauma patients, the surge in the usage of recombinant products are the collective factors driving the global market.

The growing technological advances in molecular diagnostics, inexpensive and biodegradable diagnostic products, chromogenic substrates, monoclonal antibodies, immunoassays, laboratory automation is estimated to radically change the Hemostasis diagnostics market over the following five years.